Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
2012; Springer Science+Business Media; Volume: 29; Issue: 5 Linguagem: Inglês
10.1007/s12032-012-0227-7
ISSN1559-131X
AutoresKwonoh Park, Jae‐Lyun Lee, Inkeun Park, Seongjoon Park, Yongcheol Ahn, Jin‐Hee Ahn, Shin Ahn, Cheryn Song, Jun Hyuk Hong, Choung‐Soo Kim, Hanjong Ahn,
Tópico(s)Tuberous Sclerosis Complex Research
Referência(s)